<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05618132</url>
  </required_header>
  <id_info>
    <org_study_id>2806</org_study_id>
    <nct_id>NCT05618132</nct_id>
  </id_info>
  <brief_title>ReACHallenge Trial: Acetylcholine Rechallenge After Pretreatment With Vasoactive Drugs</brief_title>
  <acronym>ReACHallenge</acronym>
  <official_title>Stepwise Treatment and Acetylcholine Rechallenge in Vasospastic Angina to Guide Patient-tailored Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to assess the feasibility and clinical value of&#xD;
      acetylcholine (ACH) rechallenge after intracoronary verapamil +- nitroglycerine in a patient&#xD;
      cohort with angina and non-obstructive coronary arteries (ANOCA).&#xD;
&#xD;
      The main questions it aims to answer are:&#xD;
&#xD;
        -  to determine the efficacy of these drugs in treating ACH-induced coronary artery spasm&#xD;
&#xD;
        -  to determine the efficacy of these drugs in preventing ACH-induced coronary artery spasm&#xD;
&#xD;
      The ACH rechallenge will take place during the index coronary function tests in patients with&#xD;
      proven ACH-induced vasospastic angina. The study is considered a feasibility study, no&#xD;
      control arm is included.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2023</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percent of ACH provoked spasm that is no longer inducible by ACH after IC injection of verapamil.</measure>
    <time_frame>Baseline</time_frame>
    <description>Is verapamil able to suppress ACH-induced coronary artery spasm?</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percent of ACH provoked spasm that is no longer inducible by ACH after sequential IC injection of verapamil and NTG.</measure>
    <time_frame>Baseline</time_frame>
    <description>Is verapamil + NTG able to suppress ACH-induced coronary artery spasm?</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percent of ACH provoked spasm that resolves after IC administration of verapamil.</measure>
    <time_frame>Baseline</time_frame>
    <description>How efficient is verapamil IC as a treatment for ACH-induced coronary artery spasm?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent of ACH provoked spasm that resolves after sequential IC administration of verapamil and NTG.</measure>
    <time_frame>Baseline</time_frame>
    <description>How efficient is verapamil and NTG IC as a treatment for ACH-induced coronary artery spasm?</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of patients with epicardial coronary artery spasm who have microvascular spasm after either verapamil or verapamil + NTG.</measure>
    <time_frame>Baseline</time_frame>
    <description>Do microvascular and epicardial vasospasm occur simultaneously and is it possible to unmask microvascular spasm with either verapamil or verapamil + NTG.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0</measure>
    <time_frame>Baseline</time_frame>
    <description>Are there safety concerns related to the proposed ACH rechallenge protocol?</description>
  </other_outcome>
  <other_outcome>
    <measure>Absolute changes in the individual, overall and summary score of the Seattle Angina Questionnaire (SAQ) from baseline to the first ambulatory control visit.</measure>
    <time_frame>Baseline, 1 month</time_frame>
    <description>Does treatment based on the current protocol improve control of angina at the first ambulatory visit compared to before the coronary function tests?</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Angina Pectoris, Variant</condition>
  <condition>Angina Pectoris; Spasm-Induced</condition>
  <condition>Angina Pectoris With Normal Coronary Arteriogram</condition>
  <arm_group>
    <arm_group_label>Vasospastic angina</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interventional diagnostic protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Acetylcholine rechallenge</intervention_name>
    <description>STEP 1 consists of verapamil 1mg IC. Angiography after 60 seconds, if spasm persists, NTG 200µg IC is given (step 2). If verapamil suppresses spasm, ACH rechallenge (ACHR) is performed after 3 minutes.&#xD;
In STEP 2, patients with persistent spasm after verapamil or with spasm after ACHR receive NTG 200µg IC. Angiography after 60 seconds, if spasm persists, NTG 200µg IC is delivered again. If refractory spasm occurs, atropine 1mg IV is given. Coronary spasm is considered suppressed once ACHR can no longer provoke spasm. NTG 200µg IC is given as final drug regardless of spasm.&#xD;
ACHR consists of ACH 100 or 200µg IC depending on the dose that previously provoked the coronary artery spasm (both microvascular and epicardial spasm).</description>
    <arm_group_label>Vasospastic angina</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinically indicated coronary angiogram in the setting of angina with non-obstructive&#xD;
             coronary artery disease (ANOCA)&#xD;
&#xD;
          -  Non-obstructive coronary artery disease is defined as the absence of coronary artery&#xD;
             stenosis ≥ 50%, or if ≥ 50% with non-ischemic resting (RFR &gt; 0.89) and hyperemic&#xD;
             indices (FFR &gt; 0.80).&#xD;
&#xD;
          -  ACH provoked epicardial and/or microvascular spasm&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &gt; 50%&#xD;
&#xD;
          -  Renal function with eGFR ≥ 40 ml/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Obstructive coronary artery disease (both chronic and acute coronary coronary&#xD;
             syndromes)&#xD;
&#xD;
          -  Any cardiomyopathy (including takotsubo stress cardiomyopathy) or severe valvular&#xD;
             disease&#xD;
&#xD;
          -  LVEF &lt; 50%&#xD;
&#xD;
          -  Long QT syndrome (LQTS) - genetic or acquired&#xD;
&#xD;
          -  Ventricular paced rhythm&#xD;
&#xD;
          -  Renal failure with eGFR &lt; 40 ml/min&#xD;
&#xD;
          -  Thyroid stimulating hormone (TSH) &lt; lower limit of normal (LLN). A subject taking&#xD;
             thyroid replacement therapy may be enrolled with TSH level below LLN if, in the&#xD;
             opinion of the investigator, the subject is in a clinically euthyroid state.&#xD;
&#xD;
          -  Known hypersensitivity or contra-indication for either acetylcholine, verapamil,&#xD;
             nicorandil or nitroglycerine.&#xD;
&#xD;
          -  Pregnant female subjects. Female subjects of child-bearing potential should be on&#xD;
             adequate contraceptive measures or are to be screened with a urine pregnancy test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tijs Bringmans</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Antwerp</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tijs Bringmans</last_name>
    <phone>+32 3 821 3843</phone>
    <email>tijs.bringmans@uza.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Antwerp</name>
      <address>
        <city>Antwerp</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tijs Bringmans</last_name>
      <email>tijs.bringmans@uza.be</email>
    </contact>
    <investigator>
      <last_name>Vincent FM Segers</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>November 8, 2022</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2022</study_first_posted>
  <last_update_submitted>January 17, 2023</last_update_submitted>
  <last_update_submitted_qc>January 17, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vasospastic angina</keyword>
  <keyword>Angina with non-obstructive coronary arteries (ANOCA)</keyword>
  <keyword>Acetylcholine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina Pectoris, Variant</mesh_term>
    <mesh_term>Microvascular Angina</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcholine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

